Repatha Lawsuit: Side Effects, Muscle Damage & Failure to Warn Claims

What Repatha Is and Who Takes It

Repatha is a PCSK9 inhibitor -- a class of injectable biologic drugs that dramatically lower LDL cholesterol by blocking a protein that reduces the liver's ability to remove LDL from blood. Approved by the FDA in 2015 for patients with familial hypercholesterolemia or established cardiovascular disease who need additional LDL reduction beyond what statins can provide, Repatha is administered by injection every two weeks or monthly.

The drug represents a major advance in cardiovascular risk reduction, with clinical trial data showing significant reduction in heart attack and stroke risk. However, plaintiffs allege that Amgen's clinical trials and post-market surveillance identified safety signals -- particularly related to neurocognitive effects and muscle-related adverse events -- that were not adequately communicated to prescribers and patients through the drug's labeling.

The Alleged Side Effects

The primary adverse events alleged in Repatha litigation include: myopathy and muscle damage (muscle pain, weakness, and in severe cases rhabdomyolysis -- breakdown of muscle tissue that can cause kidney damage); neurocognitive effects including memory problems, confusion, and cognitive impairment; and injection site reactions more severe than disclosed in labeling.

PCSK9 inhibitors as a class generated early regulatory concern about neurocognitive effects. The FDA required Amgen and other PCSK9 inhibitor manufacturers to conduct additional trials studying cognitive effects after initial reports emerged in clinical trial populations. Plaintiffs allege that Amgen's labeling minimized or inadequately characterized these risks during the period before the additional trial data was available.

The Failure to Warn Legal Theory

Pharmaceutical product liability claims most commonly proceed on failure to warn theories -- the allegation that a drug's label did not adequately inform prescribing physicians (or in some cases patients directly) about known or knowable risks associated with the drug. The learned intermediary doctrine, applicable in most states, means that pharmaceutical manufacturers discharge their duty to warn by adequately informing the prescribing physician rather than the patient directly. See also: Abilify Lawsuit.

Plaintiffs must show both that the warning was inadequate and that a different, adequate warning would have led their physician to make a different prescribing decision -- a causation requirement that can be demanding to establish. Related: Suboxone failure to warn dental claims.

Who May Qualify

Patients who received Repatha injections and subsequently experienced: significant muscle pain or weakness; rhabdomyolysis or documented myopathy; cognitive impairment or memory problems; or other serious adverse events may have claims. Medical documentation of the adverse event and its correlation with Repatha use is essential.

Given the relatively recent approval of Repatha (2015) and typical statutes of limitations, claims for injuries experienced within the last few years are most likely to be timely. Consult a pharmaceutical injury attorney for a free evaluation.

Status 2026

Repatha personal injury claims are being evaluated and filed in various jurisdictions. The litigation has not yet reached the scale of larger pharmaceutical mass torts but is developing as more patients with documented adverse events come forward. No class action settlement has been announced.

How to Get Legal Help

If you believe you qualify based on the eligibility criteria described above, the next step is a free consultation with an experienced attorney. Most plaintiff-side attorneys handling these cases work on contingency -- meaning you pay nothing unless your case results in a recovery. Bring any relevant documentation including receipts, correspondence, or evidence of the harm you experienced.

To stay current on case developments, claim deadlines, and settlement news, bookmark this page and subscribe to LawsuitWatch alerts. Coverage is updated as new court filings, settlement announcements, and eligibility changes are made public.